Horizon Investments LLC Has $3.46 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Horizon Investments LLC lifted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 9.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,263 shares of the medical instruments supplier's stock after acquiring an additional 1,323 shares during the quarter. Horizon Investments LLC's holdings in Becton, Dickinson and Company were worth $3,463,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC raised its position in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after purchasing an additional 877 shares during the last quarter. E. Ohman J or Asset Management AB raised its position in Becton, Dickinson and Company by 13.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier's stock worth $39,951,000 after purchasing an additional 20,859 shares during the last quarter. Arete Wealth Advisors LLC bought a new position in Becton, Dickinson and Company in the 3rd quarter worth approximately $767,000. Busey Bank raised its position in Becton, Dickinson and Company by 3.8% in the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier's stock worth $15,031,000 after purchasing an additional 2,399 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier's stock worth $720,089,000 after purchasing an additional 1,317,723 shares during the last quarter. Institutional investors own 86.97% of the company's stock.

Remove Ads

Insider Activity at Becton, Dickinson and Company

In related news, EVP Richard Byrd sold 1,940 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $224.91, for a total value of $436,325.40. Following the completion of the transaction, the executive vice president now directly owns 7,411 shares of the company's stock, valued at approximately $1,666,808.01. This represents a 20.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bertram L. Scott sold 700 shares of the company's stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total transaction of $159,593.00. Following the completion of the transaction, the director now directly owns 36,033 shares of the company's stock, valued at approximately $8,215,163.67. The trade was a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,984 shares of company stock worth $1,147,865 in the last quarter. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Down 0.5 %

Shares of BDX traded down $1.22 during trading hours on Friday, reaching $230.63. The stock had a trading volume of 4,372,181 shares, compared to its average volume of 1,539,839. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $251.99. The firm has a 50-day moving average of $232.58 and a 200 day moving average of $232.04. The company has a market cap of $66.22 billion, a P/E ratio of 38.31, a P/E/G ratio of 1.63 and a beta of 0.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has approved a share buyback program on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.80%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is currently 69.10%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on BDX. Barclays boosted their price objective on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. StockNews.com upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, March 5th. Finally, Piper Sandler upped their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a research report on Tuesday, January 28th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company has an average rating of "Buy" and a consensus price target of $278.29.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.